Alport syndrome
Information
- Disease name
- Alport syndrome
- Disease ID
- DOID:10983
- Description
- "A syndrome disease that is characterized by glomerulonephritis, endstage kidney disease, and hearing loss." [url:http\://en.wikipedia.org/wiki/Alport_syndrome]
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04573920 | Active, not recruiting | Phase 2 | Atrasentan in Patients With Proteinuric Glomerular Diseases | February 1, 2021 | July 28, 2026 |
| NCT03019185 | Completed | Phase 2/Phase 3 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL | March 2, 2017 | October 30, 2020 |
| NCT00622544 | Completed | A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome | July 2007 | July 2012 | |
| NCT03373786 | Completed | Phase 1 | A Study of RG-012 in Subjects With Alport Syndrome | December 22, 2017 | May 20, 2019 |
| NCT00309257 | Completed | Phase 2 | Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome | January 2004 | October 2009 |
| NCT01696253 | Completed | Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study | September 2012 | December 2017 | |
| NCT01705132 | Completed | Urinary Biomarkers of the Progression of Alport Kidney Disease | June 2012 | July 2013 | |
| NCT05133050 | Not yet recruiting | N/A | Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants | January 1, 2022 | December 31, 2026 |
| NCT05655728 | Not yet recruiting | Phase 4 | Treatment With Metformin in Chinese Children With Alport Syndrome | January 3, 2023 | April 20, 2025 |
| NCT06425055 | Recruiting | Phase 2 | Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) | June 6, 2024 | October 13, 2025 |
| NCT00481130 | Recruiting | Alport Syndrome Treatments and Outcomes Registry | September 2007 | January 2030 | |
| NCT02378805 | Recruiting | European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome | July 1995 | January 2035 | |
| NCT04947813 | Recruiting | Genotype-Phenotype Correlations in Patients With Alport Syndrome | January 1, 2021 | December 31, 2030 | |
| NCT05003986 | Recruiting | Phase 2 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | August 12, 2021 | June 1, 2025 |
| NCT05927467 | Recruiting | Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport) | May 9, 2017 | June 30, 2025 | |
| NCT06065852 | Recruiting | National Registry of Rare Kidney Diseases | November 6, 2009 | December 31, 2039 | |
| NCT06226896 | Recruiting | Effects of Dapagliflozin on Progression of Alport Syndrome | November 15, 2023 | September 30, 2026 | |
| NCT06274489 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Setanaxib in Patients With Alport Syndrome | November 27, 2023 | January 27, 2025 |
| NCT05267262 | Recruiting | Phase 2 | Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis | June 15, 2022 | June 2, 2025 |
| NCT05687474 | Recruiting | Baby Detect : Genomic Newborn Screening | September 1, 2022 | August 31, 2025 | |
| NCT03749447 | Terminated | Phase 3 | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | March 8, 2019 | August 23, 2023 |
| NCT01602835 | Terminated | Human Urine Sample Collection for Alport Nephropathy Biomarker Studies | September 2012 | May 2013 | |
| NCT02855268 | Terminated | Phase 2 | Study of Lademirsen (SAR339375) in Patients With Alport Syndrome | November 2, 2019 | September 22, 2022 |
| NCT05448755 | Unknown status | Phase 2 | A Study of ELX-02 in Patients With Alport Syndrome | November 28, 2022 | May 30, 2023 |
- Disase is a (Disease Ontology)
- DOID:225
- Cross Reference ID (Disease Ontology)
- GARD:5785
- Cross Reference ID (Disease Ontology)
- MESH:D009394
- Cross Reference ID (Disease Ontology)
- ORDO:63
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:57333009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0027706
- Exact Synonym (Disease Ontology)
- Hereditary Nephritis
- OrphaNumber from OrphaNet (Orphanet)
- 63